Amphotericin B deoxycholate
ApprovedSmall molecule
Merck & Co.Amphotericin B deoxycholate is one of 89 small molecule programs targeting Neutropenia. It is currently in Approved.
5
Indications
13
Total Trials
1
Active Trials
88
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
124 competitors in Neutropenia
#DrugCompanyPhaseTrials
1Amphotericin B deoxycholate
Merck & Co.Approved
Cubicin
BBaxter Healthcare Corporation
Phase 3
Mycostatin
GGood Molecules, LLC
Phase 3
Caspofungin Acetate
Merck & Co.Phase 3
Liposomal Lurtotecan
GileadPhase 3
Alcohol
AstellasPhase 3
Medrol
PfizerPhase 2
Cytosar
TevaPhase 2
Ellence
PfizerPhase 2
G-CSF
AArog Pharmaceuticals, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Visceral Leishmaniasis5 trials
Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis
Completed·—·Phase 3·NCT00628719·400 enrolled
Show 2 more trials
Combination Therapy in Indian Visceral Leishmaniasis
Completed·—·Phase 3·NCT00523965·624 enrolled
Aspergillosis2 trials
Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00003031·212 enrolled
Cryptococcal Meningitis2 trials
Candidiasis2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Amphotericin B deoxycholate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company